Crossmark

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Crossref DOI link: https://doi.org/10.1007/s00280-016-3097-4

Published Online: 2016-06-23

Published Print: 2016-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mizoguchi, Kosuke

Nakamura, Yoichi

Sano, Kazumi

Sato, Shuntaro

Ikegami, Yoji

Motoshima, Kohei

Takemoto, Shinnosuke

Ogawara, Daiki

Senju, Hiroaki

Sugasaki, Nanae

Ikeda, Takaya

Yamaguchi, Hiroyuki

Nakatomi, Katsumi

Fukuda, Minoru

Izumikawa, Koichi

Mukae, Hiroshi
License Information

License valid from 2016-06-23